Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells

We investigated the effects of the AMPK activator AICAR as compared to somatostatin-14 on cell viability
and GH secretion in human GH-secreting pituitary adenomas in vitro and in rat GH3 cells.
Overnight treatment with AICAR increased phospho-(threonine-172) AMPK levels (activated AMPK) in
cultured human adenomas.
As to the effects on cell viability, four adenomas out of 15 were responsive to AICAR (0.4 mM) and five
adenomas were responsive to SS-14 (100 nM). One adenoma was responsive to both somatostatin and
AICAR. The effects of cotreatment with SS-14 and AICAR were investigated in eight adenomas. In two adenomas,
the effects of AICAR + SS-14 did not exceed the effect of AICAR. In two adenomas which were not
responsive to either AICAR or SS-14, the cotreatment was able to reduce cell viability versus control. Two
adenomas were not responsive to any treatment.
As to the effects on GH secretion, nine adenomas out of 15 were responsive to AICAR. Twelve adenomas
were responsive to SS-14. Eight adenomas were responsive to both AICAR and SS-14. Cotreatment
exceeded the effect of single treatments in 4 out of 10 adenomas.
In GH3 cells, AICAR reduced the activity of p70S6 kinase, which plays an important role in cell growth.
SS-14 did not affect significantly AMPK phosphorylation and p70S6K activity but it was able to enhance
the inhibitory effect of AICAR on phospho-S6 levels. Moreover, AICAR and SS-14 reduced ERK phosphorylation
with a different time course. The combined treatment reduced phospho-ERK levels at any time
point.